Ultime notizie per Erasca (NASDAQ:ERAS) Azioni

Erasca

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Erasca Inc

News

Guidance

Mettler-Toledo Sees FY24 Adj. EPS $40.35-$40.50 Vs $40.38 Estimate

Opendoor Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) sees Q4 sales of $925.000 million-975.000 million vs $1.20 billion estimate.

OPEN

Opendoor Technologies Sees Q4 Sales $925.000M-975.000M vs $1.20B Est

OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. The company reported quarterly sales of $173.600 million which missed the analyst consensus estimate of $181.525 million by 4.37 percent. This is a 2.80 percent decrease over sales of $178.600 million the same period last year.

Earnings

Earnings Misses

OPKO Health Q3 2024 Adj. EPS $(0.09), Inline, Sales $173.600M Miss $181.525M Estimate

BARK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) affirms FY2025 sales outlook from $490.00 million-500.00 million to $490.00 million-500.00 million.

BARK

BARK Affirms FY2025 Sales Guidance from $490.00M-500.00M to $490.00M-500.00M

P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.20 by 30 percent. The company reported quarterly sales of $74.243 million which beat the analyst consensus estimate of $66.972 million by 10.86 percent. This is a 25.96 percent increase over sales of $58.942 million the same period last year.

Earnings Beats

P10 Q3 2024 Adj. EPS $0.26 Beats $0.20 Estimate, Sales $74.243M Beat $66.972M Estimate

BARK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) sees Q3 sales of $123.000 million-126.000 million vs $128.27 million estimate.

BARK Sees Q3 Sales $123.000M-126.000M vs $128.27M Est

The U.S. stock market closed at record highs Thursday after the Federal Reserve's widely expected decision to lower interest rates and Fed Chair Jerome Powell's press conference where he reassured markets by dismissing concerns about his potential resignation or removal following the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41823887/powell-dismisses-talk-of-resignation-after-trump-victory-says-policy-is-still-res">election of Donald Trump. </a>
The S&amp;P 500 — as tracked by SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — closed at 5,973 points, up 0.7% for the day.
Tech stocks outperformed the broader market, with the Nasdaq 100, tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), surging 1.5% higher to an all-time high of 21,100 points.
Notably, the combined market capitalization of the Magnificent Seven — Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Amazon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) — soared to over $17 trillion, setting a new peak.
The Dow Jones stalled after Wednesday&#8217;s 3.6% rise, while small caps eased 0.4% following a 5.8% jump the previous day.
Top-performing sectors in the S&amp;P 500 were technology, up 1.8%, followed by communications services and consumer discretionary, both up by 1.3%. Financials, which rallied the most Wednesday, lagged on Thursday, down 1.5%.
<h3 class="wp-block-heading">Fed Cuts Rates, Powell Dismisses Concerns Over His Future </h3>
The Federal Reserve cut interest rates by 0.25% to 4.5%-4.75% as expected, a reduction in the pace of easing after the larger 0.5% cut in September.
The Fed recognized robust economic momentum, with the GDP rising by 2.8% in the second quarter, and resilient consumer confidence.
Powell downplayed weak October employment data, noting that near-zero job growth was largely due to temporary factors like strikes and hurricanes rather than underlying economic weakness.
Powell described the rate cut as part of a "further recalibration" of monetary policy, which he emphasized remains "restrictive." He hinted at the possibility of more easing in the future but refrained from signaling a specific rate cut at the December meeting, stressing a data-dependent approach.
When asked if he would resign if requested by Trump, Powell responded firmly, "No," reiterating that the president does not have the legal authority to remove the Fed chair.
Following Powell's comments, market-implied expectations for a 25-basis-point rate cut in December surged to 75%, recovering from Wednesday's post-election dip.
Treasury yields pulled back sharply, with the 10-year yield dropping 10 basis points to 4.33%, almost erasing the spike from the previous day.
The U.S. dollar weakened 0.7%, while gold prices, as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), rebounded 1.8% after Wednesday&#8217;s 3% slump. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) traded up by 1% at 4:30 p.m. in New York, hitting a record-high of $76,990 during the session. 
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers On Thursday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg %</td>
</tr>
<tr>
<td>EPAM Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>)</td>
<td>233.00</td>
<td>14.95%</td>
</tr>
<tr>
<td>Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</td>
<td>13.20</td>
<td>13.69%</td>
</tr>
<tr>
<td>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>25.47</td>
<td>12.21%</td>
</tr>
<tr>
<td>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>9.38</td>
<td>11.91%</td>
</tr>
<tr>
<td>McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>)</td>
<td>607.76</td>
<td>10.64%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Losers On Thursday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Last</th>
<th>Chg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>)</td>
<td>31.11</td>
<td>-17.86%</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>21.93</td>
<td>-11.34%</td>
</tr>
<tr>
<td>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>57.09</td>
<td>-7.33%</td>
</tr>
<tr>
<td>Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>)</td>
<td>277.22</td>
<td>-5.71%</td>
</tr>
<tr>
<td>Becton, Dickinson and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>227.16</td>
<td>-5.38%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41824236/feds-interest-rate-cut-pace-expected-to-slow-economists-weigh-trumps-white-house-re">Fed&#8217;s Interest Rate Cut Pace Expected To Slow: Economists Weigh Trump&#8217;s White House Return</a></li>
</ul>
Wall Street bull illustration created using artificial intelligence via MidJourney.

Large Cap

Bonds

Broad U.S. Equity ETFs

Treasuries

Econ #s

Economics

Federal Reserve

Markets

Movers

ETFs

$BTC

AAPL

AMZN

EPAM

GOOG

GOOGL

MSFT

MTCH

NVDA

SMCI

TSLA

VTRS

Wall Street Closes At Record Highs After Reassurance From Powell: Magnificent 7 Hit $17 Trillion, Treasury Yields Erase Post-Election Spike

a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) raises FY2024 sales outlook from $560.00 million-565.00 million to $567.00 million-572.00 million.

a.k.a. Brands Holding Raises FY2024 Sales Guidance from $560.00M-565.00M to $567.00M-572.00M

VSTA

Vasta's Accumulated Subscription Revenue In The 2024 Sales Cycle Totaled R$1,.358 Billion, A 12.5% Increase Compared To The Same Period Of The 2023 Sales Cycle

H&R Block Reaffirms FY25 Outlook For Revenue Of $3.69B - $3.75B (Est $3.718B), Adjusted EPS Of $5.15 - $5.35 (Est $5.26)

Universal Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UEIC#NASDAQ">UEIC</a>) is looking for Q4 Adj EPS of $0.10-0.20 vs $0.15 analyst estimate. seessales of $99.000 million-109.000 million vs $99.85 million estimate.

UEIC

Universal Electronics Sees Q4 Adj EPS $0.10-0.20 vs $0.15 Est; Sees Sales $99.000M-109.000M vs $99.85M Est

Universal Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UEIC#NASDAQ">UEIC</a>) is looking for Q4 GAAP EPS of $(0.27)-(0.17) vs $(0.07) analyst estimate. seessales of $99.000 million-109.000 million.

Universal Electronics Sees Q4 GAAP EPS $(0.27)-(0.17) vs $(0.07) Est; Sees Sales $99.000M-109.000M

Contracts

WFRD

Weatherford Announces Three-Year Contract with ADNOC, Financial Terms Not Disclosed

CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) is looking for FY2024 Adj EPS of $1.67-1.73 vs $1.64 analyst estimate. sees sales of $885.000 million-905.000 million vs $883.61 million estimate.

CARG

CarGurus Sees FY2024 Adj EPS $1.67-1.73 vs $1.64 Est; Sees Sales $885.000M-905.000M vs $883.61M Est

Highlighting Tumor-Targeted T Cell Activation and CD40 Modulation in Solid Tumors at SITC 2024

Biotech

General

MOLN

Molecular Partners Unveils Preclinical Proof-Of-Concept For CD3 Switch-DARPin T Cell Engager And Clinical Biomarker Insights For MP0317

Sprout Social Sees Q4 Revenue $106.3M-$107.1M; Q4 Adj. EPS $0.15-$0.16.

Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) affirms FY2024 Adj EPS guidance from $1.15-1.35 to $1.15-1.35 vs $1.14 analyst estimate. Affirms FY2024 sales outlook from $1.70 billion-1.80 billion to $1.70 billion-1.80 billion vs $1.74 billion estimate.

AMRC

Ameresco Affirms FY2024 Adj EPS Guidance from $1.15-1.35 to $1.15-1.35 vs $1.14 Est; Affirms FY2024 Sales Guidance from $1.70B-1.80B to $1.70B-1.80B vs $1.74B Est

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.49) by 77.55 percent. This is a 69.44 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $88.83 million which beat the analyst consensus estimate of $84.14 million by 5.58 percent. This is a 5.80 percent increase over sales of $83.97 million the same period last year.

INGN

Inogen Q3 Adj $(0.11) Beats $(0.49) Estimate, Sales $88.83M Beat $84.14M Estimate

CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) is looking for Q4 Adj EPS of $0.50-0.55 vs $0.46 analyst estimate. sees sales of $219.000 million-239.000 million vs $225.58 million estimate.

CarGurus Sees Q4 Adj EPS $0.50-0.55 vs $0.46 Est; Sees Sales $219.000M-239.000M vs $225.58M Est

W&T Offshore Sees FY24 Total Equivalents (MBoe) 11,900 – 13,267

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Erasca (NASDAQ:<a href="https://investorplace.com/stock-quotes/eras-stock-quote/">ERAS</a>) just reported results for the second quarter of 2024.<ul><li>Erasca reported earnings per share of -29 cents. This was below the analyst estimate for EPS of -18 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/eras-stock-earnings-erasca-for-q2-of-2024/">ERAS Stock Earnings: Erasca Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ERAS Stock Earnings: Erasca Misses EPS for Q2 2024

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Erasca (ERAS – Research Report), with a price targe...

Erasca's Innovative Melanoma Treatments Prompt Buy Rating

Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on Erasca (ERAS – Research Report) today and set a price target of $4.00. The company's...

Morgan Stanley Keeps Their Buy Rating on Erasca (ERAS)

Erasca GAAP EPS of -$0.29

Chris Shibutani, an analyst from Goldman Sachs, maintained the Buy rating on Erasca (ERAS – Research Report). The associated price target was lower...

Erasca Inc. Poised for Growth: Buy Rating Maintained Amidst Promising Trial Updates and Solid Financials

Erasca: New Focus After Restructuring, But Need More Differentiation

Erasca (ERAS) announced clinical progress for naporafenib and preclinical execution across the company's RAS targeting franchise. Shannon R. Morris...

Erasca announces clinical progress for naporafenib

Analyst Jeffrey Hung of Morgan Stanley maintained a Buy rating on Erasca (ERAS – Research Report), retaining the price target of $4.00. Jeffrey Hun...

Erasca's Strategic Advancements and Promising R&D Position it as a Buy

Alec Stranahan, an analyst from Bank of America Securities, maintained the Hold rating on Erasca (ERAS – Research Report). The associated price tar...

Erasca's Promising Developments Amid Uncertainties Justify Hold Rating

Capital One Financial analyst Naureen Quibria assigned a Buy rating on Erasca (ERAS – Research Report) today and set a price target of $4.00. Naure...

Erasca's Naporafenib Progress and Strategic Focus Bolster Buy Rating

AZNCF

DAWN

ERAS

NVSEF

Press Releases

Erasca Announces Pricing of Underwritten Offering of Common Stock

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Health Care

Financing

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Erasca to Present at Upcoming Investor Conferences in June

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Erasca to Present at Upcoming Investor Conferences in September

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

Comments

Erasca

Notizie

Ultime notizie per Erasca (NASDAQ:ERAS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO